Hoechst Pakistan board approves evaluation of expansion, acquisition options

Hoechst Pakistan Limited has approved plans to evaluate strategic expansion options, including potential investments and acquisitions in the pharmaceutical sector.

In a disclosure submitted to the Pakistan Stock Exchange, the company said its board has authorised management to assess medium- to long-term growth opportunities.

The company stated that the evaluation will include potential product partnerships, investment in manufacturing assets, and acquisition of majority stakes in pharmaceutical companies, either directly or through subsidiaries.

The board has also allowed management to engage advisors to conduct technical evaluations and due diligence on proposed options before making final decisions.

The company said the move is part of its strategy to explore expansion opportunities and strengthen its position in the pharmaceutical sector.

Hoechst Pakistan is a public limited company incorporated in Pakistan under the repealed Companies Act, 1913 (Now the Companies Act, 2017). The company is engaged in the manufacturing, selling and trading of pharmaceutical and related products. 

The company has changed its name from Sanofi-Aventis Pakistan Limited to Hoechst Pakistan Limited.